Related Experiment Video
Updated: Jul 16, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
[Application of proteomics to neurological diseases]
D Brea1, I Cristobo, T Sobrino
1Laboratorio de Investigación Neurovascular, Hospital Clínico Universitario, Universidad de Santiago de Compostela, Santiado de Compostela.
Neurologia (Barcelona, Spain)
|March 17, 2007
Summary
Proteomics identifies disease biomarkers by analyzing protein expression differences in neurological conditions. This aids in discovering new diagnostic and therapeutic targets for diseases like Alzheimer's and Parkinson's.
Area of Science:
- Proteomics
- Biochemistry
- Molecular Biology
Context:
- Neurological diseases present complex challenges in diagnosis and treatment.
- Protein expression patterns can vary significantly across different neurological conditions.
- Identifying specific protein biomarkers is crucial for understanding disease mechanisms.
Purpose:
- To explore the utility of proteomics in identifying diagnostic and prognostic biomarkers for neurological diseases.
- To leverage two-dimensional electrophoresis for comparative proteomic analysis.
- To investigate protein expression differences in stroke, Alzheimer's, Parkinson's, ALS, Huntington's, and epilepsy.
Summary:
- Proteomics utilizes tools like two-dimensional electrophoresis to separate and identify proteins.
- Differential analysis of protein expression patterns in various neurological diseases can reveal key biomarkers.
- This approach allows for qualitative and quantitative comparisons of protein profiles between healthy and diseased states.
Impact:
- Identification of novel diagnostic and prognostic biomarkers for neurological disorders.
- Potential for discovering new therapeutic targets to combat neurodegenerative diseases.
- Advancing the understanding of molecular pathologies in conditions such as Alzheimer's and Parkinson's disease.
